Recon: Supreme Court tosses Purdue’s bankruptcy plan; FDA rejects Merck, Daiichi’s lung cancer drug

• Key health care topics to watch out for at the Biden-Trump debate (STAT)
• Supreme Court rejects Purdue bankruptcy plan (STAT)
• US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug (Reuters) (Endpoints)
• SoftBank Group launches AI healthcare joint venture with Tempus AI (Reuters)
• Future Pak withdraws offer to buy Vanda Pharmaceuticals (Reuters)
• Rite Aid seeks bankruptcy court approval to cut $2 billion debt (Reuters)
• Altria seeks FDA marketing order for oral nicotine pouch products (Reuters)
• US FDA approves Verona Pharma's inhaled COPD therapy (Reuters)
• GSK shares slide after US health agency narrows scope of RSV shots (Reuters)

• U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer (STAT)
• Indian regulator says 36% of inspected drug-making units had to be shut (Reuters)
• EMA Updates Pre-Authorization Procedural Advice To Cover Joint Clinical Assessments (Pink Sheet)
• EU Ministers Call For Tougher Shortage Notification Rules & Fines In Pharma Reform (Pink Sheet)
• Pakistan’s Regulator Offers Pharmacovigilance Training Amid Compliance Challenges (Pink Sheet)
• Divisional Patents Remain Divisive In Europe (Pink Sheet)
• Joint Clinical Assessments: How The EMA Will Work With EU Member States On Information Exchange (Pink Sheet)
• China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment (Reuters)
• South Korea's SK Bioscience to buy control of Germany's IDT Biologika for $244 mln (Reuters)
• German vaccine panel endorses Astra-Sanofi's RSV shot for infants (Reuters)
• Congo authorities approve mpox vaccines to try to contain outbreak (Reuters)

• Exclusive: European VC Forbion hires Dyne CEO, expands in US (STAT)
• Biogen is pursuing more dealmaking this year, with plans to spend up to $8B (Endpoints)
• Q&A: Vertex’s pain research chief on moving beyond opioids, AI and how pharma acquisitions thrive or fail (Endpoints)
• Recursion’s $200M offering; Sanofi invests $40M in Vigil Neuroscience (Endpoints)
• AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline (Endpoints)
• Silence reports Phase 1 data from rare blood disorder trial (Endpoints)
• One Medical CEO-turned-VC wants startups that are 'disruptive from within the ecosystem' (Endpoints)
• Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once (Endpoints)
• Sanofi-backed Formation Bio raises $372 million in late-stage funding round (Reuters)

• Q&A: Defining responsible AI in health care, with CHAI CEO Brian Anderson (STAT)
• Are expensive whole-body MRI scans medically useful? A new clinical trial aims to find out (STAT)
• Baxter recalls ventilation systems for charging malfunctions (MedTech Dive)
• Medtronic CFO Karen Parkhill jumps ship to HP (Reuters)
• FDA partners with Gates Foundation to support breath-based diagnostic development (MedTech Dive)

• Hospital at home program is waiting on Congress, but this New Jersey hospital isn’t (STAT)
• Supreme Court kicks Idaho emergency abortion ban back to lower court (STAT)
• Q&A: Lessons from the HHS secretary who ran Bush’s bird flu response (STAT)
• AI and rural health care: A paradigm shift in America’s heartland (STAT)
• Walgreens cuts profit view, looks to shut more stores on spending hit (Reuters)